Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Identifying surrogate markers for survival in MM

David Siegel • 13 Sep 2019
IMW 2019
Multiple Myeloma

David Siegel, MD, PhD, John Theurer Cancer Center, Hackensack, NJ, discusses the evergrowing need to identify novel surrogate markers for survival, including MRD and other endpoints, such as time to MRD negativity relapse, among others presented at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from David Siegel

Does maintenance therapy increase overall survival in myeloma?
10:09
Does maintenance therapy increase overall survival in myeloma?
David Siegel • 13 Sep 2019
Transplantation in modern myeloma therapeutics
12:34
Transplantation in modern myeloma therapeutics
David Siegel • 13 Sep 2019
The role of transplantation in the treatment of multiple myeloma
5:24
The role of transplantation in the treatment of multiple myeloma
David Siegel • 13 Sep 2019
CAR T-cells in myeloma: exploratory targets & payment models
9:28
CAR T-cells in myeloma: exploratory targets & payment models
David Siegel • 7 Sep 2018

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
David Siegel • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
David Siegel • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
David Siegel • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
David Siegel • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals